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SUMMARY
Within countries, poorer populations have greater health needs, and less access to good medical care than better off populations.  This is particularly true for tuberculosis (TB), the archetypal disease of poverty.  Similarly, innovations tend to become available to better off populations well before they become available to those who need them the most.  In a new era of innovations for TB diagnosis and treatment, it is increasingly important not only to be sure that these innovations can work in terms of accuracy and efficacy, but also that they will work, especially for the poor.  We argue that after an innovation, or a group of innovations has been endorsed based on demonstrated accuracy and/or efficacy, introduction into routine practice should proceed through implementation by research.  Cluster-randomised, pragmatic trials are suited to this approach, and permit the prospective collection of evidence needed for full impact assessment according to a previously published framework.  The novel approach of linking transmission modelling with operational modelling provides a methodology for expanding and enhancing the range of evidence, and can be used alongside evidence from pragmatic implementation trials.  This evidence from routine practice should then be used to ensure that innovations in TB control are used for positive action for all, and particularly the poor.

INTRODUCTION 
Despite recognition of the importance of social determinants as drivers of the TB pandemic,HYPERLINK \l "_ENREF_1" \o "Lonnroth, 2010 #156" ADDIN EN.CITE <EndNote><Cite><Author>Lonnroth</Author><Year>2010</Year><RecNum>156</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>156</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">156</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Lonnroth, K.</author><author>Castro, K. G.</author><author>Chakaya, J. M.</author><author>Chauhan, L. S.</author><author>Floyd, K.</author><author>Glaziou, P.</author><author>Raviglione, M. C.</author></authors></contributors><auth-address>Stop TB Department, WHO, Geneva, Switzerland. lonnrothk@who.int</auth-address><titles><title>Tuberculosis control and elimination 2010-50: cure, care, and social development</title><secondary-title>Lancet</secondary-title></titles><periodical><full-title>Lancet</full-title></periodical><pages>1814-29</pages><volume>375</volume><number>9728</number><edition>2010/05/22</edition><keywords><keyword>AIDS-Related Opportunistic Infections/diagnosis/drug</keyword><keyword>therapy/epidemiology/prevention &amp; control</keyword><keyword>HIV Infections/drug therapy</keyword><keyword>Humans</keyword><keyword>Incidence</keyword><keyword>Tuberculosis, Multidrug-Resistant/diagnosis/drug therapy/epidemiology</keyword><keyword>Tuberculosis, Pulmonary/diagnosis/drug therapy/epidemiology/*prevention &amp;</keyword><keyword>control</keyword><keyword>World Health</keyword></keywords><dates><year>2010</year><pub-dates><date>May 22</date></pub-dates></dates><isbn>1474-547X (Electronic)&#xD;0140-6736 (Linking)</isbn><accession-num>20488524</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/20488524</url></related-urls></urls><electronic-resource-num>S0140-6736(10)60483-7 [pii]&#xD;10.1016/S0140-6736(10)60483-7</electronic-resource-num><language>eng</language></record></Cite></EndNote>1 the core medical approach to TB control remains as it has been for 30 years.  It still rests on the identification of TB cases and then reducing their morbidity, mortality and infectiousness to others by treatment with combination chemotherapy.  This approach is now entering a new era with well-validated new tools for identifying and treating patients.  These new tools are either new technologies or drugs, or new approaches.  If the latter, these  may use novel combinations of existing technologies or drugs, modifications of existing tools, or combinations of all these.  These innovations are extremely welcome, but individual countries and clinics now have to make decisions about which innovations to take forward, when and where to implement them, and how to fund and sustain them.  The World Health Organization (WHO) plays an important role in guiding this decision-making process by endorsing innovations that reach certain standards through the recommendations from the Strategic and Technical Advisory Group for Tuberculosis (STAG-TB)HYPERLINK \l "_ENREF_2" \o "World Health Organization,  #161" ADDIN EN.CITE <EndNote><Cite ExcludeYear="1"><Author>World Health Organization</Author><RecNum>161</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>161</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">161</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>World Health Organization,</author></authors></contributors><titles><title>Strategic and Technical Advisory Group for Tuberculosis (STAG-TB)</title></titles><number>5 March 2011</number><dates></dates><urls><related-urls><url>http://www.who.int/tb/advisory_bodies/stag/en/index.html </url></related-urls></urls></record></Cite></EndNote>2 based on the reports of carefully constituted Expert Advisory Groups.  Examples of innovations which have recently been supported by STAG-TB include same-day diagnosis (front-loading​[1]​), LED fluorescence microscopy in 2009,HYPERLINK \l "_ENREF_3" \o "WHO STAG-TB,  #162" ADDIN EN.CITE <EndNote><Cite ExcludeYear="1"><Author>WHO STAG-TB</Author><RecNum>162</RecNum><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>162</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">162</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>WHO STAG-TB,</author></authors></contributors><titles><title>Report of the Ninth Meeting: 9-11 November 2009</title></titles><number>5 March 2011</number><dates></dates><pub-location>Geneva, Switzerland</pub-location><urls><related-urls><url>http://www.who.int/tb/advisory_bodies/stag_tb_report_2009.pdf </url></related-urls></urls></record></Cite></EndNote>3 and the GeneXpert MTB/RIF system in 2010.HYPERLINK \l "_ENREF_4" \o "WHO STAG-TB,  #163" ADDIN EN.CITE <EndNote><Cite ExcludeYear="1"><Author>WHO STAG-TB</Author><RecNum>163</RecNum><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>163</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">163</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>WHO STAG-TB,</author></authors></contributors><titles><title>Report of the Tenth Meeting: 27–29 September 2010</title></titles><number>5 March 2011</number><dates></dates><pub-location>Geneva, Switzerland</pub-location><urls><related-urls><url>http://www.who.int/tb/advisory_bodies/stag_tb_report_2010.pdf</url></related-urls></urls></record></Cite></EndNote>4   STAG-TB can also give negative recommendations, as it did in 2010 in the case of commercial TB serodiagnostic tests; making it clear that they should not be used in individuals with suspected active pulmonary or extrapulmonary TB irrespective of their HIV status.HYPERLINK \l "_ENREF_4" \o "WHO STAG-TB,  #163" ADDIN EN.CITE <EndNote><Cite ExcludeYear="1"><Author>WHo STAG-TB</Author><RecNum>163</RecNum><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>163</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">163</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>WHO STAG-TB,</author></authors></contributors><titles><title>Report of the Tenth Meeting: 27–29 September 2010</title></titles><number>5 March 2011</number><dates></dates><pub-location>Geneva, Switzerland</pub-location><urls><related-urls><url>http://www.who.int/tb/advisory_bodies/stag_tb_report_2010.pdf</url></related-urls></urls></record></Cite></EndNote>4  

In 2009 WHO adopted the GRADE approachHYPERLINK \l "_ENREF_5" \o "GRADE working group,  #152" ADDIN EN.CITE <EndNote><Cite ExcludeYear="1"><Author>GRADE working group</Author><RecNum>152</RecNum><DisplayText><style face="superscript">5</style></DisplayText><record><rec-number>152</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">152</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>GRADE working group,</author></authors></contributors><titles></titles><number>4 February 2011</number><dates></dates><pub-location>&#xD;</pub-location><urls><related-urls><url>http://www.gradeworkinggroup.org/</url></related-urls></urls></record></Cite></EndNote>5 for the synthesis of evidence to inform the formulation of guidelines and recommendations.  GRADE provides a summary statement about the quality of the evidence and a separate statement about the strength of the recommendation based on a series of criteria (See Table 1). To date the bulk of the evidence that is considered by STAG-TB is presented in the form of systematic reviews of accuracy or efficacy data.  These summarise the factors in column A of Table 1 and relate to the quality of evidence about whether innovations can work. Expert groups also consider data from implementation studies in column B (including cost and cost-effectiveness), but as yet the methodologies for systematically collecting, synthesising and presenting this evidence are not well developed.  An Impact Assessment Framework (IAF) for collating and synthesising evidence of what is required to make innovations work in routine practice has been previously published.HYPERLINK \l "_ENREF_6" \o "Mann, 2010 #113" ADDIN EN.CITE <EndNote><Cite><Author>Mann</Author><Year>2010</Year><RecNum>113</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>113</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">113</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mann, G.</author><author>Squire, S. B.</author><author>Bissell, K.</author><author>Eliseev, P.</author><author>Du Toit, E.</author><author>Hesseling, A.</author><author>Nicol, M.</author><author>Detjen, A.</author><author>Kritski, A.</author></authors></contributors><auth-address>Liverpool School of Tropical Medicine, Liverpool, UK.</auth-address><titles><title>Beyond accuracy: creating a comprehensive evidence base for TB diagnostic tools</title><secondary-title>Int J Tuberc Lung Dis</secondary-title></titles><periodical><full-title>Int J Tuberc Lung Dis</full-title></periodical><pages>1518-24</pages><volume>14</volume><number>12</number><edition>2010/12/15</edition><dates><year>2010</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1815-7920 (Electronic)&#xD;1027-3719 (Linking)</isbn><accession-num>21144235</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/21144235</url></related-urls></urls><language>eng</language></record></Cite></EndNote>6  The IAF addresses the question “Will it work?”, and by answering that question, it provides an inclusive means of answering two important implementation questions which have been posed before, namely “Does it work?” and “Is it worth it”.HYPERLINK \l "_ENREF_7" \o "Haynes, 1999 #189" ADDIN EN.CITE <EndNote><Cite><Author>Haynes</Author><Year>1999</Year><RecNum>189</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>189</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">189</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Haynes, B.</author></authors></contributors><titles><title>Can it work? Does it work? Is it worth it? The testing of healthcareinterventions is evolving</title><secondary-title>BMJ</secondary-title></titles><periodical><full-title>BMJ</full-title></periodical><pages>652-3</pages><volume>319</volume><number>7211</number><edition>1999/09/10</edition><keywords><keyword>*Clinical Trials as Topic</keyword><keyword>Cost-Benefit Analysis</keyword><keyword>Treatment Outcome</keyword></keywords><dates><year>1999</year><pub-dates><date>Sep 11</date></pub-dates></dates><isbn>0959-8138 (Print)&#xD;0959-535X (Linking)</isbn><accession-num>10480802</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/10480802</url></related-urls></urls><custom2>1116525</custom2><language>eng</language></record></Cite></EndNote>7  Evidence collated through the IAF should feed directly into the whole GRADE process, including provision of evidence for the factors in column B of Table 1, which are used in formulating the strength of a recommendation.

The best means of obtaining and using evidence about whether innovations will work has been the subject of debate in many fora.HYPERLINK \l "_ENREF_8" \o "Ramsay, 2010 #190" ADDIN EN.CITE <EndNote><Cite><Author>Ramsay</Author><Year>2010</Year><RecNum>190</RecNum><DisplayText><style face="superscript">8</style></DisplayText><record><rec-number>190</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">190</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ramsay, A.</author><author>Steingart, K. R.</author><author>Pai, M.</author></authors></contributors><titles><title>Assessing the impact of new diagnostics on tuberculosis control</title><secondary-title>Int J Tuberc Lung Dis</secondary-title></titles><periodical><full-title>Int J Tuberc Lung Dis</full-title></periodical><pages>1506-7</pages><volume>14</volume><number>12</number><edition>2010/12/15</edition><keywords><keyword>Evidence-Based Medicine</keyword><keyword>Health Policy</keyword><keyword>Humans</keyword><keyword>Policy Making</keyword><keyword>Tuberculosis/*diagnosis/prevention &amp; control</keyword><keyword>*World Health Organization</keyword></keywords><dates><year>2010</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1815-7920 (Electronic)&#xD;1027-3719 (Linking)</isbn><accession-num>21144233</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/21144233</url></related-urls></urls><language>eng</language></record></Cite></EndNote>8  The need for work in this area has been particularly highlighted by the Introduction of New Approaches and Tools sub-Working GroupHYPERLINK \l "_ENREF_9" \o "Stop TB Partnership,  #165" ADDIN EN.CITE <EndNote><Cite ExcludeYear="1"><Author>Stop TB Partnership</Author><RecNum>165</RecNum><DisplayText><style face="superscript">9</style></DisplayText><record><rec-number>165</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">165</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Stop TB Partnership,</author></authors></contributors><titles><title>Introducing New Approaches and Tools for Enhanced TB Control (INAT) Subgroup</title></titles><number>6 March 2011</number><dates></dates><urls><related-urls><url>http://www.stoptb.org/wg/dots_expansion/inat.asp</url></related-urls></urls></record></Cite></EndNote>9, (and its predecessor, the Re-Tooling Task Force), as well as the New Diagnostics Working GroupHYPERLINK \l "_ENREF_10" \o "Stop TB Partnership's New Diagnostics Working Group,  #116" ADDIN EN.CITE <EndNote><Cite ExcludeYear="1"><Author>Stop TB Partnership&apos;s New Diagnostics Working Group</Author><RecNum>116</RecNum><DisplayText><style face="superscript">10</style></DisplayText><record><rec-number>116</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">116</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Stop TB Partnership&apos;s New Diagnostics Working Group, World Health Organization. </author></authors></contributors><titles><title>Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics</title></titles><pages>WHO, 2009</pages><volume>Geneva, Switzerland</volume><dates></dates><urls></urls></record></Cite></EndNote>10 of the STOP-TB Partnership. The Bill & Melinda Gates Foundation hosted a meeting on this topic termed “Evidence for Scale-up” in December 2010, with specific reference to molecular TB diagnostics, from which a viewpoint publication is in preparation.HYPERLINK \l "_ENREF_11" \o "Cobelens F, December 1-2, 2010 #164" ADDIN EN.CITE <EndNote><Cite><Author>Cobelens F</Author><Year>December 1-2, 2010</Year><RecNum>164</RecNum><DisplayText><style face="superscript">11</style></DisplayText><record><rec-number>164</rec-number><foreign-keys><key app="EN" db-id="efp2zetzip2zrpew9f9pzx9722s9erpvppvr">164</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Cobelens F,  </author><author>Van den Hof S,</author><author>Pai M, </author><author>Squire SB, </author><author>Ramsay A, </author><author>Kimmerling M, </author></authors></contributors><titles><title>on behalf of the ‘evidence for scale-up meeting participants’ Workshop on Evidence for Scale-up of New Diagnostics for Tuberculosis. Viewpoint: evidence for scale-up of new diagnostics for tuberculosis</title></titles><pages>Manuscript in preparation</pages><volume>Bill and Melinda Gates Foundation, Seattle, USA</volume><dates><year>December 1-2, 2010</year></dates><urls></urls></record></Cite></EndNote>11 We propose the concept of “implementation by research” as an approach for filling the gap in the evidence base for scale up.  We argue that such an approach is essential to ensure that innovations in TB control are used for practical and positive action for all, especially the poor.

THE PROBLEM OF REACHING POORER POPULATIONS WITH INNOVATIONS IN TB CARE AND CONTROL: THE “INVERSE CARE LAW”.
A key problem for any health service provision or intervention is a universal phenomenon known as the “inverse care law” which was originally described in 1971 and states that “The availability of good medical care tends to vary inversely with the need for the population served”.12  Innovations, are important components of good medical care and we argue that they are subject to the same law.  Need, in this discourse, is closely related to, and determined by poverty: poorer populations within any country have greater health needs, and less access to good medical care than better off populations.  This is particularly true for TB, the archetypal disease of poverty.  First of all TB transmission is facilitated in overcrowded, poorly ventilated living conditions, the very conditions associated with poverty.13 Although it is intuitive, therefore, that TB prevalence is higher in poorer populations, and that most TB patients are poor, hard evidence to prove this association has mainly come from developed countries.14 Recently the conduct of wide-scale TB prevalence surveys in developing countries has begun to produce additional evidence that even within poorer countries, TB can be more than twice as prevalent in households within the lowest quintile of household expenditure when compared with households in the highest quintile.15  Even within less developed countries, the poor face barriers that affect them more than others16 as they proceed along the pathway to TB care.17 For these reasons it is imperative to ensure not only that innovations will work in general populations, but also that they will work for the poor.

LIMITATIONS OF CURRENT EVIDENCE FOR UPTAKE AND IMPLEMENTATION OF INNOVATIONS 
There has been progress in recent decades in reaching consensus that normative guidelines for health care interventions should be “evidence-based”.  Systematic reviews and evidence synthesis are required before innovations, be they new drug regimens,18 diagnostic approaches19 or diagnostic tools,20 are endorsed internationally for TB control.  The GRADE system is now used by WHO in formulating guidelines and recommendations.5  This brings welcome transparency and rigour to the decision-making process.  The evidence that is assessed for these guidelines and endorsements generally comes from  efficacy or demonstration studies i.e. evidence that a given innovation can work and would usefully be completed with systematically synthesised empirical evidence of effectiveness demonstrating that a given innovation will work. 

WHO endorsement is clearly not always required for innovations to be taken up and implemented at country level, but the consequences of implementing innovations that have not been independently scrutinised for accuracy or efficacy can be serious.  A good example of this is the commercial serodiagnostic tests for TB.  At least 10 different products have been widely marketed and used in South East Asia for the past decade or more without WHO endorsement.  They do not meet international standards of accuracy,21 so at best patients or health systems will have been paying for them, but with neither benefit nor harm.  At worst, patients who have falsely been diagnosed with TB will have been exposed to the risks of TB therapy without benefit, while those given false negative results may have been delayed in starting life-saving TB therapy, or even denied it completely.  This has now been recognised by STAG-TB in the 2010 negative endorsement of commercial serodiagnostics for TB.4

Once WHO endorsement has been achieved, it is not clear how adoption or implementation should proceed at country level, nor what further evidence, if any, should be collected during implementation.  In some instances implementation will be at the mercy of market forces, health system constraints, lobby groups, and strong expert opinions.  An example of this is liquid culture for Mycobacterium tuberculosis. In 2007 STAG-TB recommended that WHO assist countries such that liquid culture and DST could be implemented in National Reference Laboratories.  Cost, human resource constraints, and other factors have meant that many poorer countries have failed to establish and sustain liquid culture facilities that are accessible to the poorer sections of their societies.22  In the best instances, a public health system may make a considered decision to phase in a new innovation, but even in these cases the tendency is to implement first in facilities where success is more likely.  For example, if an innovation is dependent on an uninterrupted electricity supply in a country where mains power is unreliable, then the innovation will usually first be deployed in facilities that have the resources to install, maintain, and fuel a back-up generator.  In turn, such facilities tend to be situated in urban areas and may serve better-off populations.  Implementation tends, therefore, to start in urban areas or larger, better resourced facilities.  The lessons learned from this implementation are not relevant for implementation in less accessible locations, be they rural areas or difficult slum areas in large cities.  The result is that the hoped-for extension of implementation for the benefit of poorer populations tends not to extend as planned.  

There is an additional issue to consider with the “phasing in” of innovations in public health systems.  “Phasing in” can be accompanied by lesson-learning which helps in making decisions about discrete process issues associated with implementation, such as numbers of staff required or changes to procurement and distribution procedures.  Evidence from such lesson-learning is clearly helpful.  It should not, however, be misconstrued as hard evidence of programmatic effectiveness.  

IMPLEMENTATION BY RESEARCH AS A POTENTIAL SOLUTION – CONCEPTS AND DESIGNS
Documentation of programmatic effectiveness during implementation of an innovation requires a comparator.  The usual course of action is to compare baseline with post-innovation data in a “before-and-after” analysis.  Such analyses provide weak evidence even when a formal, clustered design is chosen (see below). Most “before-and-after” comparisons in implementation proceed without consideration of clusters or effect size, and use monitoring and evaluation to draw conclusions about effectiveness.  An additional problem with such an approach is that it will tend to produce positive results; initial implementation is deliberately selected to take place in optimal sites.  Once initial “phasing-in” has taken place, further scaling up then proceeds as a matter of course and the option of halting an inappropriate scale-up may not be considered.

A more rational approach is to make an a priori decision to implement by programmatic research employing a very pragmatic trial approach.23 Instead of implementing by selecting sites for early implementation according to likelihood of success, sites can be chosen by a formally randomised process in a prospective cluster-randomised design.24 If an explicit goal is to ensure access to the innovation by poorer populations, then the sites for randomisation could be selected because they already serve these populations.  For example, only sites serving the rural poor could be included in the randomisation; some receiving the innovation and others acting as comparators (see below).  Outcome measures can, using this approach, be chosen prospectively, formal sample size calculations undertaken based on expected size of effect, and robust, unbiased evidence on whether an innovation actually will work under routine conditions can be generated. Sites continuing to deliver services using existing approaches and technologies can provide the comparator information, or an alternative innovation could be implemented in the comparator sites to facilitate decisions on which of two (or more) potentially suitable options should be taken to scale.

The concept of pragmatic, randomised controlled trials (RCT) has been developed in detail in recent years.  They differ from explanatory RCTs in that they focus on effectiveness (does the intervention work when used in the real world, i.e. under routine normal practice?) rather than on efficacy (does the intervention work in ideal and fully controlled conditions?). Pragmatic RCTs are more suited to operational research and provide an opportunity to answer a broader range of questions than explanatory trials. It must be recognized that there is a spectrum of trial type with pure pragmatic trials at one end of the spectrum and pure explanatory trials at the other.  Quality criteria are well developed and documented for the conduct and reporting of randomized controlled trials in the CONSORT statement.25 An addendum to the CONSORT statement to improve the quality of pragmatic RCT has recently been published.26 This includes a table describing the key differences between explanatory and pragmatic trials – which is summarised in Table 2.

Options for units of randomization in Pragmatic RCTs
Randomization is arguably the most important element of a pragmatic RCT. Conventionally, individuals are allocated to study groups through a random process in order to prevent bias in the selection of group members. However, it may not be possible or even desirable to randomise individuals (e.g. if the intervention is to be delivered to entire communities), in which case groups (clusters) of individuals are randomized.  A cluster can be defined in various ways to suit the design of the particular study in question. Examples include:
Administrative Districts (one cluster = all patients attending health services within a given health district)
Enumeration Area (one cluster = all individuals in a census enumeration area)
Health Units (one cluster = all patients attending a given health unit, be it a health centre or a hospital – as defined by the study needs)
Households (one cluster = all individuals in a household)
Time-defined (one cluster = all patients attending during a defined time period, e.g. one week, two weeks, one month, or several months – this is usually used when an intervention is applied to all health unit attendees for a given time period, and then swapped back to the comparator intervention (so called “week-on, week-off” or “month-on, month-off”).
Cluster randomized designs permit the capture of health system effects (both direct and indirect) and often make use of routinely collected data. 

Options for comparator (control) arm allocation in clustered designs
The comparative clustered designs are illustrated in Figure 1, and described below.
	Before-and-after design: This design does not include a separate comparator group to the innovation group. For all participants in this design, data on the outcome measures are collected over a baseline (pre-innovation) time period, the innovation is then introduced, and finally data on the outcome measures is collected over a follow-up (post-innovation) time period.
In the absence of any other option, this design can provide important information about the possible effectiveness of an innovation. However, the absence of a contemporary comparator group means that any difference found between the pre-innovation and post-innovation study periods could be due to factors other than the innovation so the interpretation of the results from this design is often problematic. Ideally, the baseline data should be collected prospectively, so that the data collection methods (and hence data quality) are the same in the pre- and post-innovation study periods. Most commonly, however, historical control data (data which have already been collected for other purposes) are used as the baseline, and only the post-innovation data are collected prospectively.  This further weakens the validity of the final comparison. 

This is the weakest of the interventional designs, but the most commonly used in operational or implementation research, usually without any formal consideration of clusters. The following designs all include contemporary comparator arms and are amenable to randomization, so the innovation effects detected are more robust.
	Parallel groups design: Individuals or clusters are randomly allocated to the innovation and comparator groups concurrently, and data collection on the outcome measures occurs in both groups concurrently:
This gives a direct comparison of the innovation and comparator groups. If cluster randomization is to be used, the clusters can be matched in pairs for important characteristics (such as sex distribution, population size, average distance of residents from a health facility) and randomized within these pairs.
	Cross-over design: Individuals or clusters are initially randomly allocated to the innovation and comparator groups concurrently, and data collection on the outcome measures occurs in both groups concurrently over an initial study period. At the end of this period, all participants cross-over to the other arm, and data collection on the outcome measures continues in both groups concurrently over a second study period of equal time interval:
In such designs, within-cluster, or within individual evaluation allows a more precise evaluation of the effect of the innovation and therefore this design usually requires fewer participants (and fewer clusters) than a parallel groups design, but a longer time duration is needed to complete the study. There may also be important considerations for a wash-out time at the cross-over point so that any effects that occur in the first study period do not carry-over into (contaminate) the second study period.  In addition to the wash-out consideration, knowledge on how the innovation works is necessary; if the time intervals of switching the intervention are short, then either the intervention may not have adequate time to take effect or may result in an inaccurate estimate of the effect.  This design is better suited to innovations with a short term effect.
	Stepped-wedge design27: also known as dynamic wait-listed, delayed or phased intervention  is an important and ingenious modification of the cross-over design, and is particularly useful in situations where the only other alternative is the before-and-after study design. This pragmatic RCT design makes use of an implementation plan where an innovation is introduced to some areas or health facilities before others over time. The sequence by which these areas or facilities implement the innovation is randomized. Comparisons are then made over time between those areas or facilities receiving the innovation and those not yet receiving it:
As this is essentially a cross-over design where clusters act as their own comparator, the stepped-wedge design also generally requires fewer clusters than a parallel groups design, but requires more time to complete. The uni-directional switch from comparator to innovation may not permit the full within-cluster comparisons that can be employed in standard crossover designs.  It has the advantage of phasing-in an innovation over time, as would happen with uncontrolled or non-randomized implementation, so no study areas are deprived of a new innovation if this proves to have an added value.  This can remove ethical concerns about withholding the innovation from some clusters, as can be the case with parallel designs.  On the other hand, it is difficult to interrupt or stop a step-wedge design in the event of accumulating evidence that the innovation is either not useful or is actually harmful.  Such evidence may be available at an interim analysis and may be difficult to communicate to the clusters that have not yet received the innovation, but are expecting to do so.

EXAMPLES OF IMPLEMENTATION BY RESEARCH
There are several examples of health system innovations that have been tested under programmatic conditions using cluster-randomised pragmatic RCTs, including prospective assessments of the effectiveness of different strategies to promote adherence to TB therapy, ADDIN EN.CITE 28-30 assessment of the effect of educational outreach to nurses on TB case finding and primary care of respiratory illness,31  and active case-finding. ADDIN EN.CITE 32  A recent systematic review of operational research concerning WHO-endorsed interventions, concluded that prospective comparative study designs have been under-used to date, and calls for increased use of such designs in the manner proposed here (Cobelens F and Lienhardt C personal communication). 

THE USE OF IMPLEMENTATION BY RESEARCH TO PROMOTE MORE EVIDENCE BASED UPTAKE OF INNOVATIONS
If implementation of innovations by research proceeds through pragmatic RCT’s as a matter of course in several countries in different settings, then it will be possible to add more evidence about true effectiveness in routine settings to existing evidence on efficacy.  Such evidence about whether innovations will work along with more precise evidence about what resources are required for them to work will be invaluable to future policy decisions about uptake and implementation. Evidence is needed from different settings that innovations will work under routine circumstances.  For example, an innovation for MDR-TB which is costly or complex to implement may be suited to settings where MDR-TB is the dominant TB epidemiology, such as the Eastern Baltic states, but it may not be at all suited to the resource constrained settings of many countries in sub Saharan Africa where HIV-TB, not MDR-TB is the dominant TB epidemiology.

INCREASING THE POLICY AND PRACTICE RELEVANCE OF INFORMATION FROM IMPLEMENTATION BY RESEARCH – THE ROLE OF THE IMPACT ASSESSMENT FRAMEWORK
As indicated in the introduction, providing evidence that an innovation will work is necessary, but not sufficient for TB control.  It is necessary to demonstrate that it will work for poorer populations who would otherwise be disadvantaged by the workings of the inverse care law.  This requires more than the primary analyses of pragmatic effectiveness made possible by the implementation by research designs outlined above.  The kinds of additional questions that need answering are outlined in Layer 2 (Equity Analysis) and Layer 3 (Health System Analysis) of the recently published Impact Assessment Framework (see Table 3).6

Placing patient experiences of innovations in provision of TB care at the heart of implementation research through Equity Analysis (Layer 2) is currently the exception rather than the rule.  These experiences can be usefully expressed in terms of the costs incurred in care-seeking relative to ability to pay (i.e. relative to wealth quintiles, income measures, or assets).  Data for these analyses may be collected on a randomly selected subset of patients within pragmatic, cluster-randomised implementation trials, using a validated patient costing tool.33  Additional means of capturing and expressing these experiences, perhaps through qualitative research, are urgently needed.

In Layer 3, health economic analyses can be added to pragmatic, cluster-randomised implementation trials; ADDIN EN.CITE 34 greater accuracy is possible where the units of randomisation correspond to budgetary or cost centres and where costs of implementation are collected prospectively.35  Usually integral cost centres correspond to administrative units such as health districts or whole hospitals, and these constitute large clusters.   In cluster-randomised trials, large numbers of small clusters give greater statistical power to detect effect sizes in parallel group designs36 and stepped wedge designs37 so randomising by large units such as districts brings two challenges.  First, randomising large units usually results in having fewer units available for comparison, leading to low study power.38 Second, implementation of innovation activities in a large cluster will usually require more cost and time, than implementation of the same innovation in a small cluster.  If adequate numbers of large units are to be included, then the overall scale and cost of conducting this kind of implementation research can be high.  There are, however, pay-offs to consider.  More purist, cluster-randomised implementation studies which demonstrate effectiveness (see Layer 1 of the IAF – Table 3) through large numbers of small clusters may provide little information on the true economic costs or real-life implementation challenges of the innovation.  More pragmatic, cluster-randomised implementation studies based on smaller numbers of larger clusters may only detect large effect sizes, but may provide valuable cost, and cost-effectiveness data to health policy makers.  

Adding Health System and Equity Analyses to cluster randomised trials of effectiveness not only requires relatively larger cluster sizes, it also makes cluster-randomisation by multiple short blocks of time less feasible.  While this may be a useful approach for primary effectiveness analysis (Layer 1) it makes Health System and Equity analysis much more complex.  Assigning costs associated with implementing an innovation to different blocks of time is difficult.  Furthermore, patient pathways through diagnosis and treatment need time to become established with the introduction of an innovative change and costs incurred by patients along these pathways cannot be representative of actual pathways if the diagnostic and treatment algorithms are continually switching between types of provision.

SYNTHESISING A BROADER EVIDENCE BASE FOR INNOVATIONS – THE ROLE OF OPERATIONAL MODELLING
Primary implementation research is essential for the promotion of evidence-based innovations, but cannot always be carried out in every country and for every innovation in order to inform local policy on uptake and scale-up.  Furthermore, as new, well validated diagnostic and therapeutic tools for TB become available, a bewildering array of possible placements of these tools within different health system algorithms becomes possible.  Not all of these placements can be individually tested by implementation research.

Linking operational modelling with transmission modelling provides a mechanism whereby a range of implementation research data (e.g. across all three of Layers 1-3 of the IAF) can be brought together to inform policy and practice decisions.39  Furthermore, it provides a rapid and efficient means of virtual testing of different combinations of innovations to project their potential impact, reducing the need for large scale, costly primary research.  Ideal characteristics of modelling for health systems are outlined in Table 4.  

Operational modelling can be used at various stages of the decision-making process.  For example, with data from efficacy studies and initial field trials, modelling can be used to assist in defining the pragmatic RCT’s and combinations of innovations that should be tested in a given context and in providing initial estimates of their expected impact.  Data from pragmatic RCT’s can then be used to model the impact of scale-up including health system and patient costs, as well as patient and population outcomes.  At a detailed level, modelling can assist in understanding the effects of additional resources (e.g. technicians) or equipment (e.g. microscopes or GeneXpert modules) and also enables the complex interactions at district and central level within a health system to be explored and understood prior to investment.  One further use may be as an adjunct to pragmatic RCT’s that of necessity have to work with large numbers of small clusters.  As described above such RCT’s may result in accurate estimate of overall effect size, but limited estimates of patient or health system costs.  Operational modelling could be used to project health system and patient costs if the innovation were to be fully implemented within larger administrative districts, or within full scale-up.

At first sight the approach we advocate appears to require more time and cost than rolling out innovations without collating evidence in an organised fashion.  However, this is not necessarily the case; initial roll-out often proceeds in phases along a similar time scale to the one required in a step-wedge pragmatic RCT.  Nonetheless, it may be unrealistic to expect all countries to use prospective implementation by research with RCT’s designs before proceeding with implementation.  It is usually quicker and cheaper to add more circumscribed operational research questions to implementation.  In such instances we suggest use of the IAF to frame these questions, and we recommend explicit recognition of the limitations of the results that emerge when the comparator data has not been obtained through a prospective, concurrent, randomised process. Prospective, comparative, cluster-randomised pragmatic RCT’s (implementation by research) of innovations should proceed in some countries in each of the major regions which are characterised by different, dominant TB epidemiologies (HIV, M(X)DR-TB, high burden, low burden).  Evidence from such countries can then be synthesised along with evidence from more circumscribed, descriptive operational research from other countries.  This should then facilitate evidence-based implementation decisions in countries where implementation by research has not been possible.  Modelling can help in this respect.

Our approach should, in the long term save the time and cost that can be wasted on unplanned implementation that lacks evidence on effectiveness.  

CONCLUSIONS
Implementation by research using pragmatic RCT’s which collect a broad range of evidence should become the norm for innovations whose efficacy and/or accuracy has been validated.  Linking operational with transmission modelling should be used alongside these trials to provide evidence which can usefully guide large scale-up decisions on innovations, ensuring that they work under field conditions, especially for the poor.  
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Table 1: Factors used in the GRADE statements for evidence-based recommendations

	A. Factors which are consistently synthesised and reported in systematic reviews and meta-analysis(mostly based on explanatory studies)	B. Factors which are rarely synthesised and reported in systematic reviews and meta-analysis(can be collected from pragmatic implementation by research)
Quality of Evidence(may be categorised as “high”, “moderate”, “low”, or “very low” as a result of consideration of these factors)	Study designMethodological qualityInconsistencyImprecisionPublication bias	Directness of evidence (patient-important outcomes and generalisability)
Strength of Recommendation(may be categorised as “strong” or “conditional” as a result of consideration of these factors)	Quality of Evidence 	Balance between desirable and undesirable effectsValues and preferencesCosts




Table 2: Key differences between explanatory and pragmatic trials

	Explanatory	Pragmatic
Question	Efficacy: does the intervention work?	Effectiveness: does the intervention work when used in normal practice?
Setting	Well resourced, rigorously controlled conditions 	Normal clinical or public health practice
Participants	Selected. Participants who are poorly adherent are either considered as having a negative outcome or are not assessed 	Little or no selection.
Intervention	Strictly enforced and adherence is closely monitored	Applied flexibly within the requirements of normal practice
Outcomes	Often short term surrogates or process measures	Directly relevant to participants, funders, communities and healthcare practitioners
Relevance to practice	Indirect: little effort made to match trial to decision-making needs of those in the usual setting in which the intervention will be applied	Direct: designed to meet the needs of those making decisions about intervention options in the setting in which the intervention will be implemented.




Table 3: Layers of the Impact Assessment Framework requiring primary research.
Layer of Assessment		Kinds of questions being addressed for the innovation
Layer 1:EFFECTIVENESS ANALYSIS	How many additional cases will actually start treatment / achieve cure / avoid death as a result of the innovation?What will be the impact on the time to starting treatment / achieving cure 
Layer 2:EQUITY ANALYSIS	How effective is the innovation for poorer populations?What costs will patients face in accessing the innovation?
Layer 3:HEALTH SYSTEM ANALYSIS	What is the effectiveness and/or efficiency from a health system perspective?What quality assurance mechanisms need to be in place?What information systems need to be in place?What are the human resource requirements in the health system?What are the infrastructure (utilities, space) implications?




Table 4: Important qualities for a high utility modelling approach for health systems

QUALITY	DESCRIPTION
Stochastic	Ability to model uncertainty based on user defined and statistical probability distributions e.g. patient arrivals, power outages, and default probabilities.
Comprehensive	Covers all key aspects of the health system being modelled so patient, health system, and population effects can be reported
Accurate	Driven by data collected from the specific locations being modelled and validated against current performance. 
Links key factors	Models the potentially complex interactions between and within the operational and population factors that are specific to particular contexts and can effect outcomes in a significant way
Easy to change	Easily and quickly reconfigurable for different diagnostic tools and algorithms. Adjustable to model different contexts with different patient demands and treatment pathways. ‘What-If’ scenarios quickly and interactively testable.
Understandable	Presents a realistic schematic image of the health system being modelled that aids understanding and provides policy makers with confidence in the model accuracy, its outputs, and validity
Powerful	Sufficient processing power to run the models over a 3 to 4 year outcome period.

Figure 1: Illustration of different cluster-randomised trial designs with concurrent innovation and comparator arms.
A. Before- and After
Cluster	Pre-innovation study Period 	Post-innovation study Period 
1	Control	Innovation
2	Control	Innovation

B. Parallel Groups
Cluster	Study Period 
1	Innovation
2	Innovation
3	Control
4	Control

C. Cross-over
Cluster	Study Period 	Study Period 
1	Innovation	Control
2	Innovation	Control
3	Control	Innovation
4	Control	Innovation

D. Stepped-Wedge
Cluster	Study period: 
	1	2	3	4	5
1	control	innovation	innovation	innovation	innovation
2	control	control	innovation	innovation	innovation
3	control	control	control	Innovation	innovation
4	control	control	control	control	innovation






^1	  'Front-loading' or 'Same-day diagnosis' refers to consecutive sputum specimens from the same patient being examined - and results provided to health facilities - on the same day
